Thursday Morning Headlines

Yesterday was dominated by Biogen’s news on their Alzheimer drug, but there was other news including Sarepta getting slapped with a clincial hold, Gilead CEO stepping down and, although not Life Science related, Facebook getting crushed after their earnings.  Here is what I’m reading:

  • Yesterday afternoon Eisai & Biogen Revealed Promising Alzheimer’s Data But Questions Linger (Xconomy)
  • How Often Do Urgent Care Clinics Offer Antibiotics When They Shouldn’t? The answer it seems is too often. I wonder why antibiotics are becoming less and less effective. (Forbes)
  • These 10 startups made the cut for XLerateHealth’s sixth cohort (MedCity News). Ten Startups Selected for Inaugural Comcast NBCUniversal LIFT Labs Accelerator, Powered by Techstars (Venture Beat)
  • Help wanted: New CEO to run Gilead as John Milligan steps down (EndPoints)

Check out my podcast, Life Sciences Rush Hour – Investing, News, Risk Management and any other topic impacting the space, on Apple Podcasts!

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s